The biopharmaceuticals stocks to own in 2024, according to BofA
PremiumThe FlyThe biopharmaceuticals stocks to own in 2024, according to BofA
10M ago
Bristol Myers downgraded to Neutral at BofA as more clarity on execution awaited
Premium
The Fly
Bristol Myers downgraded to Neutral at BofA as more clarity on execution awaited
10M ago
Karuna Therapeutics price target raised to $330 from $197 at UBS
Premium
The Fly
Karuna Therapeutics price target raised to $330 from $197 at UBS
10M ago
Karuna deal favorable for Axsome Therapeutics, says H.C. Wainwright
PremiumThe FlyKaruna deal favorable for Axsome Therapeutics, says H.C. Wainwright
11M ago
Reviva may be most undervalued in neurology, says H.C. Wainwright
Premium
The Fly
Reviva may be most undervalued in neurology, says H.C. Wainwright
11M ago
Karuna Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
Premium
The Fly
Karuna Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
11M ago
Karuna Therapeutics downgraded to Hold from Buy at Maxim
PremiumThe FlyKaruna Therapeutics downgraded to Hold from Buy at Maxim
11M ago
Karuna Therapeutics downgraded to Market Perform from Outperform at William Blair
Premium
The Fly
Karuna Therapeutics downgraded to Market Perform from Outperform at William Blair
11M ago
Karuna Therapeutics downgraded to Sector Perform from Outperform at RBC Capital
Premium
The Fly
Karuna Therapeutics downgraded to Sector Perform from Outperform at RBC Capital
11M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100